The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma’s “next generation” weight loss drug.
Related Posts
S&P 500 futures bounce after benchmark closes in correction territory: Live updates
The three major averages are all heading for another losing week.
UPS shares tank 17% after weak guidance, plan to slash Amazon deliveries by more than half
UPS has shifted away from less profitable large contracts in recent years, while Amazon has built up its own in-house logistics empire.
UBS names its top retail stock picks this holiday shopping season
Research shows consumers want to spend this holiday season. These are the so-called ‘softline’ retail names on the UBS buy list.